

FORM PTO-1449 (Modified)		Attorney Docket No. 16930-000811US	Serial No.: 08/889,355
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: HEIDRUN ENGLER et al.	
		Filing Date: 7/8/97	Group: To be Assigned
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
<u>mu</u> AZ	Abe, A. et al., "Transduction of a Drug-Sensitive Toxic Gene into Human Leukemia Cell Lines with a Novel Retroviral Vector," <u>P.S.E.B.M.</u> 203:354-359 (1993)		
<u>mu</u> BA	Arteaga, C.L. et al., "Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice," <u>Cancer Research</u> 56:1098-1103 (1996)		
<u>mu</u> BB	Banerjee, A. et al., "Changes in Growth and Tumorigenicity following Reconstitution of Retinoblastoma Gene Function in Various Human Cancer Cell Types by Microcell Transfer of Chromosome 13," <u>Cancer Research</u> 52:6297-6304 (1992)		
<u>mu</u> BC	Bass, C. et al., "Recombinant adenovirus-mediated gene transfer to genitourinary epithelium <i>in vitro</i> and <i>in vivo</i> ," <u>Cancer Gene Ther.</u> 2(2):97-104 (1995)		
<u>mu</u> BD	Blixt, Y. et al., "Enhancement of intracellular uncoating of adenovirus in HeLa cells in the presence of benzyl alcohol as a membrane fluidizer," <u>Arch. Virol.</u> 129:265-277 (1993)		
<u>mu</u> BE	Boulikas, "Gene Therapy of Prostate Cancer: p53, Suicidal Genes, and Other Targets," <u>Anticancer Research</u> 17:1471-1506 (1997)		
<u>mu</u> BF	Brewster, S.F. et al., "Gene Therapy in Urological Oncology: Principles, Strategies and Potential," <u>Eur. Urol.</u> 25:177-182 (1994)		
<u>mu</u> BG	Cairns, P. et al., "Loss of heterozygosity at the RB locus is frequent & correlates with muscle invasion in bladder carcinoma," <u>Oncogene</u> 6:2305-2309 (1991)		
<u>mu</u> BH	Cooper, M.J. et al., "Safety-modified episomal vectors for human gene therapy," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 94:6450-6455 (1997)		
<u>mu</u> BI	Curiel, D.T. et al., "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 88:8850-8854 (1991)		
<u>mu</u> BJ	Dalesandro, J. et al., "Cardiac and Pulmonary Replacment," <u>J. Thoracic Cardio. Surg.</u> 111(2):416-422 (1996)		
<u>mu</u> BK	Fujimoto, K. et al., "Frequent Association of p53 Gene Mutation in Invasive Bladder Cancer," <u>Cancer Research</u> 52:1393-1398 (1992)		
<u>mu</u> BL	Ginsberg, H.S. et al., "Role of early region 3 (E3) in pathogenesis of adenovirus disease," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 86:3823-3827 (1989)		
<u>mu</u> BM	Good, N.E. et al., "Hydrogen Ion Buffers for Biological Research," <u>Biochemistry</u> 5(2):467-477 (1966)		
<u>mu</u> BN	Goodrich, D.W. et al., "Expression of the Retinoblastoma Gene Product in Bladder Carcinoma Cells Associates with a Low Frequency of Tumor Formation," <u>Cancer Research</u> 52:1968-1973 (1992)		
<u>mu</u> BO	Grenay, H. et al., "Characterizatio of Imidazoline Binding Protein(s) Solubilized from Human Brainstem: Studies with [³ H]Idazoxan and [³ H]Clonidine," <u>Neurochem. Int.</u> 25(2):183-191 (1994)		

FORM PTO-1449 (Modified)		Attorney Docket No. 16930-000811US	Serial No.: 08/889,355
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: HEIDRUN ENGLER et al.	
		Filing Date: 7/8/97	Group: To be Assigned
<u>mw</u> BP	Greenberg, R. et al., "Intravesical AD32 (N-Trifluoroacetyladiamycin-14-Valerate) in the Treatment of Patients with Refractory Bladder Carcinoma - Clinical Efficacy, Pharmacology, and Safety," <u>Proc. Am. Urol. Assoc.</u> 153 Supp 233A:19 (1995)		
<u>mw</u> BQ	Hemström, C. et al., "Gene Product of Region E4 of Adenovirus Type 5 Modulates Accumulation of Certain Viral Polypeptides," <u>J. Virol.</u> 62(9):3258-3264 (1988)		
<u>mw</u> BR	Huang, S. et al., "A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product," <u>Nature</u> 350:160-162 (1991)		
<u>mw</u> BS	Ji, W. et al., "Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA," <u>J. Viral Hep.</u> 4:167-173 (1997)		
<u>mw</u> BT	Kaneda, Y. et al., "Prevention of Restenosis by Gene Therapy," <u>Annals N.Y. Acad. Sci.</u> 811:299-310 (1997)		
<u>mw</u> BU	Koç, O.N. et al., "Transfer of Drug Resistance Genes Into Hemotopoietic Progenitors to Improve Chemotherapy Tolerance," <u>Sem. Oncol.</u> 23(1):46-64 (1996)		
<u>mw</u> BV	Lee, R.J. et al., "Lipidic Vector Systems for Gene Transfer," <u>Crit. Rev. Ther. Drug Carrier Sys.</u> 14(2):173-206 (1997)		
<u>mw</u> BW	Li, Q. et al., "Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy," <u>Hum. Gene. Ther.</u> 4:403-409 (1993)		
<u>mw</u> BX	Makarov, S.S. et al., "Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 93:402-406 (1996)		
<u>mw</u> BY	Marshall, E., "Gene Therapy's Growing Pains," <u>Science</u> 269:1050-1055 (1995)		
<u>mw</u> BZ	Miller, N. et al., "Targeted vectors for gene therapy," <u>FASEB J.</u> 9:190-199 (1995)		
<u>mw</u> CA	Monson, F.C. et al., "Indigocarmine as a quantitative indicator of urothelial integrity," <u>J. Urol.</u> 145:842-845 (1991)		
<u>mw</u> CB	Morris, B.D. et al., "Adenoviral-mediated gene transfer to bladder <i>in vivo</i> ," <u>J. Urol.</u> 152:506-509 (1994)		
<u>mw</u> CC	Murayama, Y. et al., "Antisense Oligonucleotides to p53 Tumor Suppressor Suppress the Induction of Apoptosis by Epidermal Growth Factor in NCI-H 596 Human Lung Cancer Cells," <u>Antisense Nucl. Acid Drug Devel.</u> 7:109-114 (1997)		
<u>mw</u> CD	Niidome, T. et al., "Binding of Cationic α -Helical Peptides to Plasmid DNA and Their Gene Transfer Abilities into Cells," <u>J. Biol. Chem.</u> 272(24):15307-15312 (1997)		
<u>mw</u> CE	Nolta, J.A. et al., "Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 93:2414-2419 (1996)		
<u>mw</u> CF	Parsons, C.L. et al., "Bladder surface glycosaminoglycans: an epithelial permeability barrier," <u>J. Urol.</u> 143:139-142 (1990)		

FORM PTO-1449 (Modified)		Attorney Docket No. 16930-000811US	Serial No.: 08/889,355
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: HEIDRUN ENGLER et al.	
		Filing Date: 7/8/97	Group: To be Assigned
<u>W</u> CG	Pinnaduwege, P. et al., "Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells," <u>Biochim. Biophys. Acta</u> 985:33-37 (1989)		
<u>W</u> CH	Plank, C. et al., "The Influence of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems," <u>J. Biol. Chem.</u> 269(17):12918-12924 (1994)		
<u>W</u> CI	Raper, S.E. et al., "Safety and Feasibility of Liver-Directed Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolemia," <u>Annals Surgery</u> 223(2):116-126 (1996)		
<u>W</u> CJ	Rosenberg, S.A., "The Immunotherapy and Gene Therapy of Cancer," <u>J. Clin. Oncol.</u> 10(2):180-199 (1992)		
<u>W</u> CK	Sandberg, J.W. et al., "Improving Access to Intestinal Stem Cells as a Step Toward Intestinal Gene Transfer," <u>Human Gene Therapy</u> 5:323-329 (1994)		
<u>W</u> CL	Spandidos, D.A. et al., "Expression of the Normal H-ras1 Gene can Suppress the Transformed and Tumorigenic Phenotypes Induced by Mutant ras Genes," <u>Anticancer Research</u> 10:1543-1554 (1990)		
<u>W</u> CM	Takahashi, R. et al., "The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 88:5257-5261 (1991)		
	et al., "Nouvelles utilisations de mammifères. Utilisation d'un vecteur peptidique," <u>CR Acad. Sci III</u> 32:275-287 (1997)		
<u>W</u> CO	Wills, K.N. et al., "Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer," <u>Hum. Gene Ther.</u> 5:1079-1088 (1994)		
<u>W</u> CP	Wills, K.N. et al., "Gene therapy for hepatocellular carcinoma: Chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene," <u>Cancer Gene Ther.</u> 2(3):191-197 (1995)		
<u>W</u> CQ	Wu, G.Y. et al., "Receptor-mediated Gene Delivery and Expression in Vivo," <u>J. Biol. Chem.</u> 263(29):14621-14624 (1988)		
<u>W</u> CR	Xiao, X. et al., "Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA _A α_1 containing receptors and increases inferior collicular seizure sensitivity," <u>Brain Res.</u> 756:76-83 (1997)		
<u>W</u> CS	Yew, N.S. et al., "Optimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells," <u>Human Gene Therapy</u> 8:575-584 (1997)		
<u>W</u> CT	Cancer Facts & Figures 1995, <u>Am. Canc. Soc.</u> 5-11 (1995)		
EXAMINER	Michael C. Walker DATE CONSIDERED 9.15.94		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.